Successfully reported this slideshow.
Your SlideShare is downloading. ×

Ad

Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Presentación del ESC Congress 2022
Scott D Salomon e a...

Ad

Martina Amiguet Comins
DELIVER Trial
Espacio reservado para
la imagen del ponente
Background & Objectives Inclusion criter...

Ad

Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background & Objectives Study population Results Concl...

Ad

Ad

Ad

Ad

Ad

Ad

Check these out next

1 of 9 Ad
1 of 9 Ad

More Related Content

More from Sociedad Española de Cardiología (20)

DELIVER Trial

  1. 1. Martina Amiguet Comins Espacio reservado para la imagen del ponente Presentación del ESC Congress 2022 Scott D Salomon e al. N Engl J Med. 2022 Doi: 10.1056/NEJMoa2206286 DELIVER Trial Dapagliflozin Evaluation to improve the LIVEs of patients with PReserved Ejection Fraction Heart Failure DELIVER
  2. 2. Martina Amiguet Comins DELIVER Trial Espacio reservado para la imagen del ponente Background & Objectives Inclusion criteria & study design Study population Results Conclusions Presentación del ESC Congress 2022 Scott D Salomon e al. N Engl J Med. 2022 Doi: 10.1056/NEJMoa2206286 ENDPOINTS PRIMARY ENDPOINT Time to first occurrence of any of the components of the composite CV death + HF hospitalization + Urgent HF visit SECONDARY ENDPOINTS • Change from baseline in the total symptom score of KCCQ at 8 months • Total number of HF events • Time to the ocurrence of CV death • Time to the ocurrence of death from any cause SAFETY ENDPOINT Serious AEs, AEs leading to treatment discontinuation, amputations, AEs leading to amputation and potential risk factor fro AEs leading to amputqations affecting the lower limbs. SGLT2i have shown benefit in CVD, HFrEF and CKD, regardless of diabetes status. HFpEF is an heterogeneous entity with modest benefit of prognosis drugs until the publication of EMPEOR preserved. Full population LVEF<60% DELIVER Study Design Salomon et al Eur J Heart Fail 2021
  3. 3. Martina Amiguet Comins Espacio reservado para la imagen del ponente Background & Objectives Study population Results Conclusions Presentación del ESC Congress 2022 Scott D Salomon e al. N Engl J Med. 2022 Doi: 10.1056/NEJMoa2206286 Inclusion criteria & study design DELIVER Trial DELIVER Study Design Salomon et al Eur J Heart Fail 2021
  4. 4. Martina Amiguet Comins Espacio reservado para la imagen del ponente Study population Results Conclusions Presentación del ESC Congress 2022 Scott D Salomon e al. N Engl J Med. 2022 Doi: 10.1056/NEJMoa2206286 Background & Objectives Inclusion criteria & study design DELIVER Trial Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction https://doi.org/10.1016/j.jchf.2021.11.006
  5. 5. Martina Amiguet Comins Espacio reservado para la imagen del ponente Study population Results Conclusions Presentación del ESC Congress 2022 Scott D Salomon e al. N Engl J Med. 2022 Doi: 10.1056/NEJMoa2206286 Background & Objectives Inclusion criteria & study design DELIVER Trial 18% NNT=32
  6. 6. Martina Amiguet Comins Espacio reservado para la imagen del ponente Study population Results Conclusions Presentación del ESC Congress 2022 Scott D Salomon e al. N Engl J Med. 2022 Doi: 10.1056/NEJMoa2206286 Background & Objectives Inclusion criteria & study design DELIVER Trial
  7. 7. Martina Amiguet Comins Espacio reservado para la imagen del ponente Study population Results Conclusions Presentación del ESC Congress 2022 Scott D Salomon e al. N Engl J Med. 2022 Doi: 10.1056/NEJMoa2206286 Background & Objectives Inclusion criteria & study design DELIVER Trial Consistency is observed in the previously specified subgroups
  8. 8. Martina Amiguet Comins Espacio reservado para la imagen del ponente Study population Results Conclusions Presentación del ESC Congress 2022 Scott D Salomon e al. N Engl J Med. 2022 Doi: 10.1056/NEJMoa2206286 Background & Objectives Inclusion criteria & study design DELIVER Trial Serious adverse events leading to discontinuation were similar between dapaglifozin and placebo
  9. 9. Martina Amiguet Comins Espacio reservado para la imagen del ponente Study population Results Conclusions Presentación del ESC Congress 2022 Scott D Salomon e al. N Engl J Med. 2022 Doi: 10.1056/NEJMoa2206286 Background & Objectives Inclusion criteria & study design DELIVER Trial In the largest and most inclusive trial of patients with HFpEF and HFmrEF, dapagliflozin reduced the composite outcome of CV death + WHF Dapagliflozin was effective in patients with recent HF hospitalization, in those with prior reduced LVEF, with no attenuation of the effect in the higher LVEF group “Estos datos apoyan el empleo de iSGLT2 como terapia fundacional en la Insuficiencia Cardíaca, independientemente de la FEVI”

×